Table 6.
Multilevel modeling of systolic blood (SBP) pressure values at 90 days
| PREVIEW | IMPROVE | ADVANCE | INSIST | eNOVA | BSCORE | EXCELLENT | ||
|---|---|---|---|---|---|---|---|---|
| Intercept | mmHg | 130.3 | 133.4 | 124.3 | 120.1 | 91.6 | 112.0 | 101.6 |
| Patient-related variables | ||||||||
| Age | per year | 0.069 | 0.064 | |||||
| SBP at initial diagnosis of hypertension | per mmHg | 0.125 | 0.142 | 0.097 | 0.062 | 0.059 | ||
| SBP at baseline | per mmHg | 0.275 | 0.186 | 0.205 | ||||
| Diabetes | if present | 1.801 | ||||||
| Retinopathy | if present | 4.706 | ||||||
| Highly vulnerable to uncontrolled hypertension cluster | if present | 3.029 | 3.405 | |||||
| Cardiovascular risk score | per point (0−11 scale) | (−0.653) | ||||||
| Number of risk factors | per factor | (−0.462) | ||||||
| Total cholesterol at baseline | per unit | 0.011 | ||||||
| Concomitant antihypertensive treatment: ACE inhibitor | if present | (−4.598) | (−2.436) | |||||
| Concomitant antihypertensive treatment: calcium antagonist | if present | (−1.913) | (0.857) | |||||
| Concomitant antihypertensive treatment: beta blocker | if present | (1.600) | ||||||
| Concomitant antihypertensive treatment: other | if present | (3.307) | ||||||
| Concomitant lipid-lowering treatment | if present | −2.556 | ||||||
| Nonadherent days in past 4 weeks | per day | 0.408 | ||||||
| Patient-reported nonadherence behavior | if reported | 2.091 | ||||||
| Patient-rated adherence | per point (0–100 scale) | −1.902 | ||||||
| Physician-rated adherence | per point (0–100 scale) | −0.161 | −0.142 | −0.117 | −0.186 | −0.151 | ||
| Physician-related variables | ||||||||
| Years since medical school graduation (in practice) | per year | 0.110 | 0.108 | 0.105 | 0.278 | |||
| Hypertensive patients seen in past 12 months | per patient | −0.003 | ||||||
| Correct responses to questions related to evidence-based hypertension management | per response (0–4) | (1.011) | ||||||
| Correct blood pressure targets for diabetic patients | if all correct | (2.451) | (3.263) | |||||
| Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment initiation | per practice (0–6) | −0.652 | ||||||
| Self-reported practices consistent with evidence-based guidelines re: SBP threshold for treatment intensification | per practice (0–6) | −0.372 |
Abbreviation: ACE, angiotensin converting enzyme.